AASLD: Calcineurin Inhibitor Does Not Influence Outcome of Liver Transplantation in HCV-Positive Recipients

[Guest guest]

http://www.docguide.com/news/content.nsf/news/852576140048867A85257665005EA77E

BOSTON -- November 5, 2009 -- The outcome for patients undergoing a liver transplant for hepatitis C virus (HCV)-related liver disease is not affected by the calcineurin inhibitor chosen for treatment, according to a study presented here at the Liver Meeting 2009, the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Aguilera, Hepatogastroenterology Service, Hospital Universitario La Fe, Valencia, Spain, and colleagues reported findings from their prospective, randomised study on October 31.In one-third of liver transplants, recurrent hepatitis C is aggressive. Immunosuppression influences the natural history of this infection. In HCV-infected transplant recipients, an association exists between the state of the patient's immunosuppression and the outcome after transplantation. However, data are conflicted in regard to the

potential effect of calcineurin inhibitors on the outcome.

more...